Currently Viewing:
In Focus Blog

Cancer Drugs Driving 340B Growth Even More Than Understood, Report Finds

Mary K. Caffrey
The report, commissioned by the Community Oncology Alliance, finds that Medicare Part B cancer drug spending rose 123% in 340B hospitals from 2010 to 2013, but only 31% in non-340B hospitals; it fell 5% in community practices in the same period.
The report stated, “Oncology drug reimbursement has increased by 86% at continuously enrolled 340B hospitals and 58% at non-340B hospitals. Although some of this growth is a function of changing demographics and advancements in chemotherapy (which typically come with an increased cost), the disparity in growth rates between 340B and non-340B hospitals speaks to the disproportionate role that 340B hospitals play in the acquisition of community oncology practices.”

“This is, in large part,” the report concluded, “a function of the sizeable profits that 340B hospitals realize on Medicare and commercial reimbursement of oncology drugs.”

Among the findings:
  • The 340B program grows each year. In 2010, there were 89 new hospitals enrolled classified as “Disproportionate Share,” or DSH, along with 342 non-DSH. A hospital’s DSH status is calculated based on whether patients qualify for Medicare Part A, Medicaid or Supplemental Security Income. The number of new enrollees rose each until 2014 brought 324 new DSH enrollees and 1222 non-DSH.

     
  • The report found that new enrollees—those arriving in 2010 or later—accounted for 23% of Medicare Part B outpatient drug spending in 2013.
     
  • Medicare spending in 2013 on oncology drugs in 340B hospitals outpaced that of non-340B hospitals, $3.064 billion to $2.672 billion, even though overall hospital revenues are higher among the non-340B hospitals, $1.968 trillion vs $1.411 trillion for 340B.
     
  • The gap in spending per-beneficiary in Medicare Part B FFS for oncology drugs between 340B hospitals and community oncology practices is large and growing: in 2010, 340B hospitals spent $1722 per patient per day, while community practices spent $1226. In 2013, the per-patient, per-day figure had grown to $1920 for 340B hospitals but barely budged for community practices, to $1266, at a time when the cost of cancer drugs is soaring.

The report confirms the overall conclusions of the GAO findings. The agency said, “While it is not unlawful for hospitals to benefit financially from the drug discount program," the report said, such practices are “not consistent with the legislative intent of the 340B program.” It noted that taxpayers generally and patients individually suffer harm, since Medicare Part B beneficiaries are responsible for 20% copayment, which will rise along with drug prices.

That report also questioned whether all healthcare provided in 340B hospitals is appropriate, and states, “Absent a change in financial incentives, potentially inappropriate spending on drugs may continue.”

Today’s report comes as the Health Resources and Services (HRSA) takes comment on a proposed guidance that would increase oversight and double the number of conditions needed to qualify for 340B status. Some hospital groups have questions whether the rules will simply make oncology care more bureaucratic and inconvenient for patients, and whether limits on access will result.

“The 340B program is very administratively complex and costly to administer now,” Beth Feldpush, senior vice president of advocacy and policy for America’s Essential Hospitals said when the guidance was issued. “For our members that rely on the savings, I could see where if HRSA narrowed the program so much, a hospital could say the costs to run this program may outweigh (the benefit of) participation in it.”

Comment on the guidance continues through October 27, 2015.

AJMC staff Surabhi Dangi-Garimella, PhD, contributed to this report.
 
 


 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up